← All trials
NCT03953170
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 27, 2019
- Primary completion
- Jun 30, 2021
- Completion date
- Jun 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Allegheny Health NetworkLead sponsor
- Allegheny Health NetworkReponsible party - principal investigator
- ShireCollaborator
- Allegheny Health NetworkOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.